The approval of Sacituzumab govitecan—an ADC juxtaposing an anti-TROP-2 antibody with SN-38, a topoisomerase-I inhibitor, via a hydrolysable linker-highlights TROP-2’s extracellular domain exposure and ubiquity across aggressive subtypes as pivotal for targeted agents alike [16]—provides new options for the treatment of patients with resistant or metastatic triple-negative breast cancer and is more and more under investigation also in hormone receptor-positive disease. This evidence concerns the gene TACSTD2 and triple-negative breast carcinoma.